Nano Dimension LTD Schedule 13D activist filings

Tang Capital Management and affiliated entities have increased their beneficial ownership of Nano Dimension Ltd. to 7.9% by acquiring an additional 2,422,999 shares.

Oramed Pharmaceuticals Inc. reports changes in beneficial ownership of Nano Dimension Ltd. ordinary shares, including option and put option transactions.

Nano Dimension and Murchinson Ltd. have reached a settlement agreement, leading to the cancellation of the July 31, 2026 Extraordinary General Meeting and a reconstitution of the Company's Board of Directors.

Tang Capital Management proposes a merger with Nano Dimension, offering $1.60 per share in cash, and has acquired a 6.8% stake in the company.

Oramed Pharmaceuticals has increased its stake in Nano Dimension to 7.2% and publicly declared opposition to the company's proposed transaction with Infinite Epigenetics.

Murchinson Ltd. and affiliated shareholders have formally demanded a special meeting to replace directors and restrict the board's authority over major transactions.

Oramed Pharmaceuticals Inc. has increased its beneficial ownership in Nano Dimension Ltd. to 5.2%, expressing strong dissatisfaction with the issuer's management and strategic direction.

Oramed Pharmaceuticals and CEO Nadav Kidron disclose a 5% activist stake in Nano Dimension Ltd., signaling intent to influence governance and strategy.

Anson Funds Management LP and its affiliates have filed an exit Schedule 13D, indicating they no longer hold a reportable beneficial ownership stake in Nano Dimension Ltd.

Anson Funds Management LP and its affiliates have substantially decreased their beneficial ownership in Nano Dimension Ltd. to 7.5% and initiated short economic exposure through derivative agreements.